Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer

Personalization of Prostate Cancer Care Through Integration of Data

In this presentation, given during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Philips, Ilya Gipp, MD, PhD, a medical officer and oncology solutions subject matter expert with Philips in Atlanta, Georgia, discusses solutions for integrating data to personalize prostate cancer care. He first describes positive trends and challenges in prostate cancer care, noting that data silos across service lines and service providers remain a key barrier to effective and efficient treatment. Dr. Gipp describes the prostate cancer service line as beginning with early detection, progressing to diagnosis and staging, treatment selection, therapy planning and deployment, and assessment and follow-up. He then focuses on the actionability and insightfulness of information, and how to synthesize data throughout the cancer care pathway using magnetic resonance imaging (MRI). Dr. Gipp remarks that while MRI is often used in diagnosis, to benefit from the data, MRI must be the modality used at all points from screening to post-therapy assessment. For example, MRI can generate images similar to CT scans for radiation dose planning as well as guiding dose painting to offer localized, non-uniform radiation dose distribution. He summarizes by comparing the traditional approach to cancer care with a state-of-the-art model that employs biomarker imaging, image-guided multi-modality navigated fusion biopsies, digital pathology, and focal therapies.

Read More

Experience with 18F-rhPSMA7.3 for Prostate Cancer

In this 6-minute presentation, presented during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Blue Earth Diagnostics, Wolfgang Weber, MD, Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany (TUM), discusses 18F-rhPSMA7(.3) as a promising tracer for imaging prostate cancer for primary staging and in the case of biochemical recurrence, explaining that limited renal excretion facilitates evaluation of the prostate and the prostate bed before surgery. Dr. Weber explains that prospective registration trials have completed accrual, and the use of radiohybrid prostate-specific membrane antigen ligands (rhPSMAs) for therapy of prostate cancer is being evaluated preclinically.

Read More

Doctor Knows Best? Why Prostate Cancer Care Must Be Transformed Into Digital Health

In this 14-minute program presented during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Siemens, Michael H. Johnson, MD, FACS, Associate Professor and Vice Chair of Urology at Washington University in St. Louis, discusses why digital health solutions must revolutionize prostate cancer care. Dr. Johnson asserts that we are at an inflection point in medicine when digital medicine has the opportunity to transform and improve patient care and treatment in ways that are both instantaneous but also far-reaching.

Read More

PSMA PET-CT: Clinical Applications

In this presentation, supported by Telix Pharmaceuticals, Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center in Myrtle Beach, South Carolina, presents advances in PSMA PET-CT imaging for staging, prognosis, and clinical management of prostate cancer. He first describes prostate cancer metastases before explaining prostate-specific membrane antigen (PMSA) and how it serves as an effective molecular target for metastatic prostate cancer. Dr. Shore reviews the pros and cons of conventional imaging techniques such as bone scintigraphy, computed tomography (CT), and multiparametric MRI (mpMRI). While treatment guidelines recommend conventional imaging, he notes that bone scans and CT positively identify less than 10% of men with biochemical recurrence and in particular lesions that are <1 cm with a PSA <20 ng/mL. He then compares the benefits of PSMA as an imaging target: it is upregulated in prostate cancer, the degree of expression is positively correlated with tumor state and higher risk of recurrence, there is a positive correlation between PSMA expression and Gleason score/grade, and it may be targeted with either a small molecule or antibody. Dr. Shore reviews numerous studies demonstrating the effectiveness of PSMA PET-CT in metastatic prostate cancer but indicates there is insufficient data on the use of PSMA PET-CT in patients with hormone-naïve disease. He then considers patient selection and points out several downsides including increased cost of care and the potential impact of health disparities. He concludes that PSMA PET-CT is particularly useful in detecting prostate cancer that is otherwise not identified by conventional imaging and in cases with low serum PSA.

Read More